Jim Miller is president of PharmSource Information Services, Inc., and publisher of Bio/Pharmaceutical Outsourcing Report, tel. 703.383.4903, Twitter@JimPharmSource, firstname.lastname@example.org(, http://www.pharmsource.com/.
European CDMOs want into the US market, but entry options are limited.
The trend of exits from the CMO industry looks to be gaining momentum.
As payers refuse to cover new drugs, CMOs take a hit.
The CMO industry's value proposition is limiting its market penetration.
Changes in company ownership shake up the CMO industry.
The R&D model is in transition and creating new demands on contract services providers.
Ongoing changes create new opportunities for CROs and CMOs.
Practicality of implementation should be a part of vision in the bio/pharmaceutical industry.
Are strategic partnerships in clinical research a model for CMC services?